Cancer is the second leading cause of death in the Western world
By 2030, the global burden is expected to grow to 21 million new cases and 13 million deaths simply due to growth and aging of the population. Despite the great advances in surgery, radiotherapy, chemotherapy, and more recently the introduction of targeted molecular therapies and immunotherapies, most solid tumours remain fatal once they are metastatic. A major breakthrough in cancer treatment has recently occurred: the immunotherapeutic manipulation of tumour microenvironment to help the patient’s own immune system to fight the tumour. Among these new treatments, some viruses with natural oncolytic properties can be genetically modified to efficiently target tumours and promote immunogenic cancer cell death. MeasovirTM belongs to this new class of oncovirotherapy.